Construction and Validation of A Novel Predictive Model Based on Chromatin Regulators in Endometrial Cancer

Author:

Zhao Ling1,Peng Chuyu1,Wang Haolun2,Ou Shanshan1,Li Ting1,Wei Peiru1,Zhu Jianbin1,Liu Bo1

Affiliation:

1. Center of Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China

2. Day-Care Unit, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China

Abstract

Chromatin regulators (CRs) are substantially associated with the prognosis and immunotherapy responses in multiple cancers. However, comprehensive studies related to the prognostic prediction of CRs in endometrial cancer (UCEC) still remains lacking. Therefore, first, we constructed a prognostic model for UCEC associated with 23 CRs using a univariate Cox regression model as well as the glmnet R package. Then, based on the median risk scores, we separated the UCEC sufferers into the high risk set and low risk set, in which the proportion of sufferers with pathological grade G3 and clinical-stage III–IV is higher in the high risk one. Furthermore, we investigated the association of independent prognostic factors, immunotherapy-related scores, GO, KEGG pathways, and drug sensitivity between both groupings. We identified the high risk set tended to have lower IPS, microsatellite instability, and tumor mutational load. GO and KEGG suggested an enrichment of genes related to ribosome biogenesis, RNA processing and metabolism, viral defence, translational regulation, and calmodulin-binding in the high-risk one, while the other one related to cilia movement, microtubule movement, axonal components, and calmodulin-binding. Drug sensitivity assay showed sensitive doxorubicin could be applied to the high-risk patients. All in all, our team successfully built and validated a predictive model for CRs that predicts the overall survival of UCEC patients, which may provide a potential new direction for prognosis prediction and therapeutic target selection for UCEC patients.

Publisher

American Scientific Publishers

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3